Centre Hospitalier Regional De La Citadelle
- Address
- lock Available on a paid plan
Cardiology and Cardiovascular Research
At Centre Hospitalier Regional De La Citadelle, the Cardiology department is running a broad portfolio of studies in cardiovascular diseases, focusing on conditions such as atrial fibrillation, heart failure, hypertension, acute coronary syndrome, and chronic kidney disease linked to cardiovascular risk. These trials are designed to improve treatment effectiveness, reduce complications, and test new approaches for long-term heart and vascular care.
- Research on rhythm disorders, including atrial fibrillation, with attention to safer and more effective antithrombotic strategies
- Studies in heart failure and cardiomyopathy aiming to improve symptoms and clinical outcomes
- Trials in hypertension and cardiovascular risk reduction to support better prevention and disease control
- Evaluation of new therapies for atherosclerotic cardiovascular disease and related high-risk conditions
The site’s cardiovascular research also includes studies that connect heart disease with broader metabolic and kidney-related problems, reflecting a strong interest in integrated care for complex patients.
Immunology, Neuromuscular, and Autoimmune Disorders
A major part of the research landscape at this Belgian hospital involves immune system diseases and neuromuscular disorders. Trials are studying generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, spinal muscular atrophy, and muscular dystrophies, with the goal of testing new therapies and understanding whether they can improve strength, function, and daily living.
- Studies in generalized myasthenia gravis and related antibody-mediated muscle weakness
- Research in spinal muscular atrophy and muscular dystrophy focused on preserving motor function
- Trials in chronic inflammatory demyelinating polyneuropathy evaluating longer-term disease control
- Investigation of therapies for rare autoimmune neuromuscular diseases to improve patient outcomes
These studies emphasize both symptom relief and disease modification, helping advance care for patients with rare and often disabling conditions.
Pediatric Hematology and Leukemia Studies
The site has a particularly active program in pediatric hematology and acute leukemia. Ongoing trials address acute lymphoblastic leukemia, acute myeloid leukemia, and lymphoblastic lymphoma in children and young people, with the purpose of improving survival, refining risk-based treatment, and reducing relapse.
- Trials in acute lymphoblastic leukemia and lymphoblastic lymphoma aimed at improving cure rates in children and adolescents
- Research in acute myeloid leukemia focused on better disease control and personalized treatment decisions
- Studies exploring minimal residual disease and response assessment to guide therapy more precisely
- Work on improving outcomes for relapsed or high-risk blood cancers through new treatment strategies
This area reflects a strong commitment to advancing care for young patients with aggressive blood cancers through more tailored and effective treatment approaches.
Pediatric and Rare Solid Tumors
Research at Centre Hospitalier Regional De La Citadelle also includes important studies in pediatric oncology and rare solid tumors, such as neuroblastoma, medulloblastoma, Ewing sarcoma, rhabdomyosarcoma, ependymoma, and renal tumors. These trials are aimed at improving survival, reducing recurrence, and finding better ways to combine surgery, radiation, and systemic treatment.
- Studies in neuroblastoma focused on improving outcomes in high-risk disease
- Trials in medulloblastoma and ependymoma evaluating treatment optimization for brain tumors in children and adolescents
- Research in Ewing sarcoma and rhabdomyosarcoma testing ways to strengthen frontline and relapsed-disease care
- Studies in renal tumors and other rare pediatric cancers aimed at improving response and long-term disease control
The work in this field combines precision in diagnosis with efforts to improve cure rates for some of the most challenging childhood cancers.
Respiratory, Gastrointestinal, and Inflammatory Disease Research
The trial portfolio also covers respiratory diseases, digestive system diseases, and broader inflammatory conditions. Studies are being conducted in asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn's disease, with the aim of improving disease control and testing new treatment options.
- Trials in asthma and chronic cough evaluating better symptom control and medication reduction
- Research in chronic obstructive pulmonary disease and pulmonary fibrosis focused on long-term respiratory outcomes
- Studies in ulcerative colitis and Crohn's disease assessing new ways to induce and maintain remission
- Work on allergic and eosinophilic airway disease to support more targeted treatment
These studies reflect a strong interest in chronic inflammatory disorders where better control can significantly improve quality of life.
Kidney, Metabolic, and Other Specialized Clinical Research
Beyond its core cardiovascular focus, the site contributes to research in kidney disease, metabolic disorders, and selected diagnostic and therapeutic techniques. Current studies include chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis, type 2 diabetes, and fertility-related care, often with the goal of improving disease progression, outcomes, or diagnostic accuracy.
- Trials in chronic kidney disease and related renal conditions assessing ways to slow progression
- Research in type 2 diabetes and cardiometabolic risk to support better long-term management
- Studies in fertility and reproductive health exploring ways to improve the chance of pregnancy and live birth
- Additional work in diagnostic techniques and supportive care to refine clinical decision-making
This mix of studies shows a broad clinical research profile that extends across chronic disease management, reproductive health, and supportive interventions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 21 therapeutic areas and 15 of 216 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 214 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 56 by active trials.
- 1AstraZeneca AB4active
lock +55 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Regional De La Citadelle
lock Showing 1 of 134 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy | Edgewise Therapeutics Inc. | Phase II | Not Recruiting | Dec 2022 | — |
IMP list
lock Showing 1 of 216 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vincristine Sulfate | 12 | Unknown | 2015-06-02 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
